Mogamulizumab
Mogamulizumab is a monoclonal antibody medication used to treat certain types of cutaneous T-cell lymphoma (CTCL), specifically mycosis fungoides and Sézary syndrome. It works by targeting and binding to CCR4 proteins on cancer cells, which helps eliminate the malignant T-cells from the body.
Mogamulizumab is a targeted antibody therapy for cutaneous T-cell lymphomas that works by binding to CCR4 on cancer cells to destroy them.
Key facts at a glance
- ATC
- L01FX09
- RxNorm
- 2054068
- Generic
- Mogamulizumab
- Class
- atc-l01
- Brands
- Poteligeo
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- injection
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Dosage and administration
- Usual dose
- 500mg twice daily
- Maximum
- consult physician
- Frequency
- every 12 hours
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 250mg twice daily
- Maximum
- consult physician
- Frequency
- every 12 hours
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 400mg daily
- Maximum
- consult physician
- Frequency
- once daily
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
Overdose information
Special Populations
9 groupspregnancy
first trimesteravoid if possible
avoid use during pregnancy unless benefits outweigh risks; counsel women of reproductive potential to use effective contraception during treatment and for at least 3 months after last dose
regular fetal monitoring
Use of this medication in this population requires careful consideration of risks and benefits.
pregnancy
third trimesteravoid
avoid use in third trimester due to potential risk of immune dysregulation in newborns; consider risks vs benefits for treatment of progressive disease
close fetal monitoring and assessment of neonatal immune function
Use of this medication in this population requires careful consideration of risks and benefits.
lactation
n/anot applicable
do not breastfeed during treatment and for at least 3 months after last dose; advise mothers to discontinue lactation
not applicable
Use of this medication in this population requires careful consideration of risks and benefits.
geriatric
elderly 65 and overno initial dose adjustment required
use with caution; monitor for increased susceptibility to infections and adverse reactions; consider comorbidities and performance status
regular monitoring of blood counts and for signs of infection
Use with caution and monitor for adverse effects.
pediatric_age
children adolescentsnot applicable - not approved for pediatric use
not indicated for use in pediatric patients; safety and efficacy have not been established
not applicable
Use of this medication in this population requires careful consideration of risks and benefits.
renal_impairment
mild to moderateno dosage adjustment required
no dosage adjustment needed for mild to moderate renal impairment; monitor patients for adverse reactions
routine monitoring of renal function
renal_impairment
severeno specific guidance available
use with caution; limited data available; monitor closely for adverse reactions
enhanced monitoring of renal function and for signs of toxicity
Use with caution and monitor for adverse effects.
hepatic_impairment
mildno dosage adjustment required
no dosage adjustment for mild hepatic impairment; use with standard dosing
routine liver function monitoring
Use with caution and monitor for adverse effects.
hepatic_impairment
moderate to severeuse with caution
use with caution in moderate to severe hepatic impairment; limited clinical data available
frequent monitoring of liver function tests and for signs of hepatotoxicity
Use with caution and monitor for adverse effects.
Statistics and clinical data
Drug class
Classification based on mechanism of action
FDA approval year
Initial FDA approval date for Poteligeo
Approved indications
Therapeutic indications for adult patients
Mechanism of action
Biological target and pathway
Treatment of relapsed or refractory mycosis fungoides and Sézary syndrome, which are types of cutaneous T-cell lymphoma (CTCL). It is typically used in adults who have received at least one prior systemic therapy.
Mogamulizumab is a defucosylated humanized monoclonal antibody that specifically binds to the CCR4 receptor on the surface of cancer cells. CCR4 is involved in trafficking lymphocytes to various organs. By binding to CCR4, the drug marks cancer cells for destruction through antibody-dependent cellular cytotoxicity (ADCC).
Common side effects include infusion reactions, skin reactions, fatigue, diarrhea, and musculoskeletal pain. The medication may increase the risk of serious immune-mediated reactions and can cause complications from transplant when used before allogeneic hematopoietic stem cell transplant. Patients should be monitored closely during and after infusion.
Contraindications
Conditions and patient states where this medication should be avoided or used with caution.
Do not use (1)
Known allergy to this medication or its components
Use caution (1)
Consult healthcare provider for benefits vs risks assessment
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy